Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 20;2(7):100355.
doi: 10.1016/j.xcrm.2021.100355. Epub 2021 Jul 2.

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

Alison Tarke  1   2 , John Sidney  1 , Nils Methot  1 , Esther Dawen Yu  1 , Yun Zhang  3 , Jennifer M Dan  1   4 , Benjamin Goodwin  1 , Paul Rubiro  1 , Aaron Sutherland  1 , Eric Wang  1 , April Frazier  1 , Sydney I Ramirez  1   4 , Stephen A Rawlings  4 , Davey M Smith  4 , Ricardo da Silva Antunes  1 , Bjoern Peters  1   4 , Richard H Scheuermann  1   3   5 , Daniela Weiskopf  1 , Shane Crotty  1   4 , Alba Grifoni  1 , Alessandro Sette  1   4
Affiliations

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

Alison Tarke et al. Cell Rep Med. .

Abstract

The emergence of SARS-CoV-2 variants with evidence of antibody escape highlight the importance of addressing whether the total CD4+ and CD8+ T cell recognition is also affected. Here, we compare SARS-CoV-2-specific CD4+ and CD8+ T cells against the B.1.1.7, B.1.351, P.1, and CAL.20C lineages in COVID-19 convalescents and in recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines. The total reactivity against SARS-CoV-2 variants is similar in terms of magnitude and frequency of response, with decreases in the 10%-22% range observed in some assay/VOC combinations. A total of 7% and 3% of previously identified CD4+ and CD8+ T cell epitopes, respectively, are affected by mutations in the various VOCs. Thus, the SARS-CoV-2 variants analyzed here do not significantly disrupt the total SARS-CoV-2 T cell reactivity; however, the decreases observed highlight the importance for active monitoring of T cell reactivity in the context of SARS-CoV-2 evolution.

Keywords: CD4; CD8; COVID-19; SARS-CoV-2; T cells; VOCs; vaccines.

PubMed Disclaimer

Conflict of interest statement

A. Sette is a consultant for Gritstone, Flow Pharma, CellCarta, Arcturus, Oxfordimmunotech, and Avalia. S.C. is a consultant for Avalia. All of the other authors declare no competing interests. LJI has filed for patent protection for various aspects of vaccine design and identification of specific epitopes.

Figures

None
Graphical abstract
Figure 1
Figure 1
T cell responses of COVID-19 convalescent individuals against ancestral and variant SARS-CoV-2 spike (S) PBMCs of COVID-19 convalescent individuals (n = 28) were stimulated with the S MPs corresponding to the ancestral reference strain (black) and the B.1.1.7 (gray), B.1.351 (red), P.1 (orange), and CAL.20C (light blue) SARS-CoV-2 variants. (A) The gating strategy for the AIM assay is illustrated by representative graphs defining S-specific CD4+ or CD8+ T cells by expression of OX40+CD137+ and CD69+CD137+, respectively. These graphs depict 1 of the COVID-19 convalescent donors from this study tested with the S MPs corresponding to each of the VOCs tested. (B) Percentages of AIM+ (OX40+CD137+) CD4+ T cells. (C) Percentages of AIM+ (CD69+CD137+) CD8+ T cells. (D) IFN-γ spot-forming cells (SFCs) per million PBMCs. (E) IL-5 SFCs per million PBMCs. (F and G) The data shown in (B) and (C) are plotted to show the titration of the S MPs (1 μg/mL, 0.1 μg/mL, and 0.01 μg/mL) for CD4+ (F) and CD8+ (G) T cells for each SARS-CoV-2 variant. The geometric mean of the 0.1 μg/mL condition is listed above each titration. Paired comparisons of ancestral S MPs versus each of the variants were performed by 1-tailed Wilcoxon test and are indicated by the p values in (B)–(D). In all of the panels, the bars represent the geometric mean. See also Figures S1, S2, S4, and S5 and Tables S1–S3.
Figure 2
Figure 2
T cell responses of COVID-19 convalescent individuals against ancestral and variant SARS-CoV-2 proteomes PBMCs of COVID-19 convalescent individuals (n = 28) were stimulated with MPs for the entire viral proteome corresponding to the ancestral reference strain (black) and the B.1.1.7 (gray), B.1.351 (red), P.1 (orange), and CAL.20C (light blue) SARS-CoV-2 variants. (A) Percentages of AIM+ (OX40+CD137+) CD4+ T cells for the total reactivity. (B) Percentages of AIM+ (CD69+CD137+) CD8+ T cells for the total reactivity. (C) Percentages of AIM+ (OX40+CD137+) CD4+ T cells for each MP. (D) Percentages of AIM+ (CD69+CD137+) CD8+ T cells for each MP. All of the bars represent the geometric mean. See also Figure S1, S2, S4, and S5 and Tables S1–S3.
Figure 3
Figure 3
T cell responses of COVID-19 vaccinees against ancestral and variant SARS-CoV-2 S PBMCs of Pfizer/BioNTech BNT162b2 (n = 14, triangles) and Moderna mRNA-1273 COVID-19 vaccinees (n = 15, circles) were stimulated with the S MPs corresponding to the ancestral reference strain (black) and the B.1.1.7 (gray), B.1.351 (red), P.1 (orange), and CAL.20C (light blue) SARS-CoV-2 variants. (A) The gating strategy for the AIM assay is illustrated by representative graphs defining S-specific CD4+ or CD8+ T cells by the expression of OX40+CD137+ and CD69+CD137+, respectively. These graphs depict one of the COVID-19 vaccinated donors from this study tested with the S MPs corresponding to each of the VOCs tested. (B) Percentages of AIM+ (OX40+CD137+) CD4+ T cells. (C) Percentages of AIM+ (CD69+CD137+) CD8+ T cells. (D) IFN-γ SFCs per million PBMCs. (E) IL-5 SFCs per million PBMCs. (F) Percentages of IFN-γ were calculated from the total IFN-γ and IL-5 SFCs per million PBMCs. (G and H) The data shown in (B) and (C) are also plotted showing the S MPs titration (1, 0.1, and 0.01 μg/mL) for CD4+ (G) and CD8+ (H) T cells with each SARS-CoV-2 variant. The geometric mean of the 0.1 μg/mL condition is listed above each titration. Paired comparisons of the ancestral reference strain-based S MP versus each of the variants were performed by one-tailed Wilcoxon test and are indicated by the p values in (B)–(D). In all of the panels, the bars represent the geometric mean. See also Figures S1 and S3–S5 and Tables S1–S3.
Figure 4
Figure 4
SARS-CoV-2 T cell epitope sequences affected by the variants CD4+ and CD8+ T cell epitopes of the ancestral strain identified in a previous study were analyzed as a function of the number and percentage of responses that are or are not conserved across the B.1.1.7 (gray), B.1.351 (red), P.1 (orange), and CAL.20C (light blue) SARS-CoV-2 variants. (A–D) The SARS-CoV-2 epitopes for the most immunodominant SARS-CoV-2 proteins in terms of numbers and percentage of response are shown for CD4+ (A and B) and CD8+ (C and D) T cells. (E–H) The SARS-CoV-2 epitopes for the S protein only in terms of numbers and percentage of response are shown for CD4+ (E and F) and CD8+ (G and H) T cells. (I–M) The peptide-binding algorithm data of mutated versus wild-type epitopes are shown for CD8+ (I–L) and for the effect of the mutations on CD8+ T cell epitopes, in which each instance was categorized as a function of whether the binding capability of the mutated peptide was increased (>2-fold), neutral, or decreased (<2-fold) (M). See also Table S4.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kirby T. New variant of SARS-CoV-2 in UK causes surge of COVID-19. Lancet Respir. Med. 2021;9:e20–e21. - PMC - PubMed
    1. Volz E., Mishra S., Chand M., Barrett J.C., Johnson R., Geidelberg L., Hinsley W.R., Laydon D.J., Dabrera G., O’Toole Á., COVID-19 Genomics UK (COG-UK) consortium Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021;593:266–269. - PubMed
    1. Davies N.G., Abbott S., Barnard R.C., Jarvis C.I., Kucharski A.J., Munday J.D., Pearson C.A.B., Russell T.W., Tully D.C., Washburne A.D., CMMID COVID-19 Working Group. COVID-19 Genomics UK (COG-UK) Consortium Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055. - PMC - PubMed
    1. Tegally H., Wilkinson E., Lessells R.J., Giandhari J., Pillay S., Msomi N., Mlisana K., Bhiman J.N., von Gottberg A., Walaza S. Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat. Med. 2021;27:440–446. - PubMed
    1. Voloch C.M., da Silva Francisco R., Jr., de Almeida L.G.P., Cardoso C.C., Brustolini O.J., Gerber A.L., Guimarães A.P.C., Mariani D., da Costa R.M., Ferreira O.C., Jr., Covid19-UFRJ Workgroup, LNCC Workgroup, Adriana Cony Cavalcanti Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. J. Virol. 2021;95 e00119-21. - PMC - PubMed

Publication types

Substances

Supplementary concepts

-